GlassScriptPhysician profile
David R Carroll
NPI 1679562730
$17,596.58
in general payments reported to CMS, 2019-2025
32 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $585 · 2021: $550 · 2022: $5,038 · 2023: $6,723 · 2024: $3,368 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $3,526 · Travel and Lodging: $1,592 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $3,526.13 |
| Travel and Lodging | $1,591.87 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $14,118.47 | 2019-2025 | Davinci Xi, Da Vinci Surgical System |
| Kerecis Limited | $536.95 | 2020-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Davol INC. | $429.33 | 2022-2025 | Phasix Mesh |
| Ethicon US, LLC | $419.11 | 2019-2025 | Enseal, Harmonic, Echelon Flex |
| Access Pro Medical, LLC | $386.19 | 2022-2023 | Matriderm |
| Medtronic, INC. | $193.61 | 2024-2025 | Symbotex, Signia |
| Abbvie INC. | $179.66 | 2021-2025 | Dalvance |
| Smith+Nephew, INC. | $175.98 | 2019-2025 | Collagenase Santyl |
| Takeda Pharmaceuticals U.S.A., INC. | $174.94 | 2020-2025 | Gattex |
| Novo Nordisk INC | $159.63 | 2024-2025 | Wegovy |
| Baxter Healthcare | $120.66 | 2019-2021 | |
| Hologic Sales and Service, LLC | $93.73 | 2025 | Coolseal Generator, Magtrace, Magseed |
| Sanara Medtech INC. | $90.88 | 2020-2023 | Celleraterx |
| Tela Bio, INC. | $60.04 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Myriad Genetic Laboratories, INC. | $52.09 | 2025 | Myrisk |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $51.99 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $43.19 | 2022-2025 | Exparel |
| Acera Surgical, INC. | $33.37 | 2019-2021 | |
| Heron Therapeutics, INC. | $29.21 | 2021-2022 | |
| Standard Bariatrics, INC. | $26.84 | 2022 | |
| Aroa Biosurgery Incorporated | $25.31 | 2020 | |
| Pfizer INC. | $23.41 | 2024 | |
| Innocoll Pharmaceuticals Limited | $22.56 | 2021 | |
| Organogenesis INC. | $22.21 | 2024 | |
| Ambu INC. | $21.98 | 2022 | |
| Endogastric Solutions, INC | $20.47 | 2022 | |
| Solventum Corporation | $17.12 | 2025 | Prevena |
| Medline Industries LP | $16.48 | 2022 | |
| Getinge USA Sales, LLC | $15.53 | 2019 | |
| Coopersurgical, INC. | $13.23 | 2020 | |
| Lucid Diagnostics INC. | $13.22 | 2024 | |
| Medela LLC | $9.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.